FDA Approves Cladribine (Mavenclad) for Relapsing MS FDA Approves Cladribine (Mavenclad) for Relapsing MS
The US Food and Drug Administration today approved cladribine for treatment of patients with relapsing multiple sclerosis who have had insufficient response to other agents.FDA Approvals
In this report we describe a rare case of concurrent AQP4-positive NMOSD and neurosyphilis. A 60-year-old man was admitted to our hospital with a complaint of progressive weakness in his legs for one month. T2-weighted magnetic resonance images of the spinal cord showed longitudinal extensive lesions at C7–T7. The rapid plasma reagin test and T. pallidum particle agglutination assay performed using patient serum and cerebrospinal fluid (CSF) were positive. Additionally, the AQP4-immunoglobulin (Ig) G was detected in the serum and CSF. The patient's symptom gradually improved after penicillin and methylprednisolo...
Publication date: Available online 22 June 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Tom A. Fuchs, Stefano Ziccardi, Michael G. Dwyer, Leigh E. Charvet, Alexander Bartnik, Rebecca Campbell, Jose Escobar, David Hojnacki, Chana Kolb, Devon Oship, Jeta Pol, Michael T. Shaw, Curtis Wojcik, Faizan Yasin, Bianca Weinstock-Guttman, Robert Zivadinov, Ralph H.B. BenedictAbstractBackgroundGrowing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual...
Conclusion: PwMS prioritize accessibility, affordability, insurance coverage, and comprehensiveness in MS healthcare services.
ConclusionCooccurrence of a seizure in a patient with MS may complicate the management process. In this review, we tried to provide answers to the frequently asked questions, considering the best available scientific evidence and expert opinion.
ConclusionsThis study indicates that there was no significant correlation between IgG antibodies against Toxocara and variables such as gender and age. Based on the statistical analysis, there was no significant difference in Toxocara seropositivity between our control population with MS and RA patients.
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, aVoters for Cures advocate from South Carolina who reminds us what ’s at stake in the broader public policy debate around medical innovation, access and affordability.
Condition: Multiple Sclerosis Intervention: Dietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeks Sponsors: University of Novi Sad, Faculty of Sport and Physical Education; CarnoMed Recruiting
Condition: Relapsing Multiple Sclerosis Intervention: Drug: SAR442168 Sponsor: Sanofi Not yet recruiting
Multiple sclerosis (MS) and stroke are two common causes of death and disability worldwide. The relationship between these two diseases remains unclear. Effective early preventative measures and treatments are...
(1) Identify the proportion of participants with spinal cord dysfunction (SCD) reporting each of 10 job benefits and compare the proportions between participants with spinal cord injury (SCI) and multiple sclerosis (MS), and (2) examine if diagnostic criteria, demographics, education level, and functional limitations are associated with the number of job benefits received.